Europe Meglitinide Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

Europe Meglitinide Market is segmented by Geography (Germany, Spain, Italy, France, United Kingdom, Russia, Rest of Europe). The report offers the value (in USD) and Volume (in Unit) for the above segments.

Europe Meglitinide Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

Europe Meglitinide Market Size

View Global Report
Europe Meglitinide Market Summary
Study Period 2019 - 2030
Base Year For Estimation 2024
Forecast Data Period 2025 - 2030
Historical Data Period 2019 - 2023
CAGR 2.30 %

Major Players

Europe Meglitinide Market Major Players

*Disclaimer: Major Players sorted in no particular order

Compare market size and growth of Europe Meglitinide Market with other markets in Healthcare Industry

Biotechnology

Pharmaceuticals

Healthcare IT

Medical Devices

Animal Health

Device Drug Combination

Europe Meglitinide Market Analysis

The Europe Meglitinide Market is expected to register a CAGR of 2.3% during the forecast period.

The COVID-19 epidemic has significantly affected the market for insulin drugs and devices. Patients with type-1 diabetes are more affected by COVID-19. Since people with diabetes already have weakened immune systems, COVID-19 causes those immune systems to deteriorate rapidly. Those with diabetes are more likely to experience significant complications than healthy persons. During COVID-19, the manufacturers of insulin drugs worked with local governments to provide insulin drugs to diabetes patients.

Meglitinides are a type of non-sulfonylurea insulin secretagogues with a fast onset and short duration of action. They stimulate glucose-sensitive first-phase insulin release, lowering the risk of hypoglycemia. Meglitinides cause the body to release more insulin in people with type 2 diabetes, who have chronically high blood sugar levels.

The World Health Assembly agreed on a Resolution to strengthen diabetes prevention and control in May 2021. It recommends actions such as increasing access to diabetes medicines and health products and assessing the feasibility and potential value of establishing a web-based tool to share information relevant to market transparency for diabetes medicines and health products. The rapidly increasing incidence and prevalence of diabetic patients and healthcare expenditure in Europe are indications of the increasing usage of diabetic drug products. Therefore, owing to the aforementioned factors the studied market is anticipated to witness growth over the analysis period.

This is driving the demand for Meglitinides in Europe, thereby driving the market in focus during the forecast period.

Europe Meglitinide Industry Overview

The Meglitinides market is fragmented, with manufacturers like Novo Nordisk, Glenmark, and Novartis having a global market presence and the market is highly competitive due to generic drugs manufacturers' presence.

Europe Meglitinide Market Leaders

  1. Novo Nordisk

  2. Glenmark

  3. Kissei

  4. Novartis

  5. Biocon

  6. *Disclaimer: Major Players sorted in no particular order
Europe Meglitinide Market Concentration
Need More Details on Market Players and Competiters?
Download PDF

Europe Meglitinide Market News

  • March 2023: A Randomized, Open-Label, Controlled, Parallel-group, Multicenter Trial is being conducted to evaluate the efficacy and safety of INS068 once daily (QD) in subjects with type 2 diabetes not adequately controlled with oral antidiabetic drugs compared to insulin Glargine QD for 26+26 weeks.
  • January 2023: OXJournal reviewed the effects of meglitinides as a class of oral medications for treating type 2 diabetes, especially in young adults.

Europe Meglitinide Market Report - Table of Contents

1. INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Drivers
  • 4.3 Restraints
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Bargaining Power of Suppliers
    • 4.4.2 Bargaining Power of Consumers
    • 4.4.3 Threat of New Entrants
    • 4.4.4 Threat of Substitute Products and Services
    • 4.4.5 Intensity of Competitive Rivalry

5. Market Segmentation

  • 5.1 Drug
    • 5.1.1 Meglitinides
  • 5.2 Geography
    • 5.2.1 Germany
    • 5.2.2 Spain
    • 5.2.3 Italy
    • 5.2.4 France
    • 5.2.5 United Kingdom
    • 5.2.6 Russia
    • 5.2.7 Rest of Europe

6. MARKET INDICATORS

  • 6.1 Type-1 Diabetes Population
  • 6.2 Type-2 Diabetes Population

7. COMPETITIVE LANDSCAPE

  • 7.1 Company Profiles
    • 7.1.1 Novo Nordisk
    • 7.1.2 Novartis
    • 7.1.3 Glenmark
    • 7.1.4 Boehringer Ingelheim
    • 7.1.5 Biocon
    • 7.1.6 Kissei Pharmaceuticals
    • 7.1.6.1 Other Key Players
  • *List Not Exhaustive
  • 7.2 Company Share Analysis

8. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
* We will provide a segment-wise breakdown (Value and Volume) for all the countries covered under the Table of Contents. **Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments.
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Europe Meglitinide Industry Segmentation

Despite not sharing a structural relationship with sulfonylureas, meglitinides are secretagogues. With a different mode of action than sulfonylureas, they cause the pancreas to secrete insulin. Repaglinide, Nateglinide, and Mitiglinide are the three readily available medicines. The Europe Meglitinide Market is segmented by Geography (Germany, Spain, Italy, France, Russia, United Kingdom, Rest of Europe). The report offers the value (in USD) and Volume (in Unit) for the above segments. We will provide a segment-wise breakdown (Value and Volume) for all the countries covered under the Table of Contents.

Drug Meglitinides
Geography Germany
Spain
Italy
France
United Kingdom
Russia
Rest of Europe
Need A Different Region or Segment?
Customize Now

Europe Meglitinide Market Research FAQs

What is the current Europe Meglitinide Market size?

The Europe Meglitinide Market is projected to register a CAGR of 2.30% during the forecast period (2025-2030)

Who are the key players in Europe Meglitinide Market?

Novo Nordisk, Glenmark, Kissei, Novartis and Biocon are the major companies operating in the Europe Meglitinide Market.

What years does this Europe Meglitinide Market cover?

The report covers the Europe Meglitinide Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Europe Meglitinide Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.

Europe Meglitinide Industry Report

Statistics for the 2025 Europe Meglitinide market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Europe Meglitinide analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.